Skip to main content

Modern Locoregional Treatment of Colorectal Cancer Liver Metastases

  • Chapter
Current Controversies in Cancer Care for the Surgeon

Abstract

Worldwide, colorectal cancer (CRC) is one of the most common malignancies. At presentation, metastatic spread is observed in approximately 20 % of patients with a further 50 % developing metastases during their disease course. In patients who develop metastases, 80 % have some form of liver involvement. The only treatment for patients with isolated colorectal cancer liver metastases (CRLM) associated with potential long-term survival and cure is surgery. Unfortunately, most patients (75–80 %) have disease that is not amenable to surgical intervention. However, recent advances in all areas of the management of CRLM have resulted in more numerous treatment options for this population of patients. Developments in diagnosis, medical therapy (chemotherapy, targeted therapy), nonsurgical locoregional therapy (ablation, embolization, hepatic artery infusion chemotherapy), and surgical therapy have expanded the treatment armamentarium for patients with CRLM and subsequently increased the complexity of management. Many newer therapies/treatment strategies have proven effective; however, there is debate regarding the ideal clinical implementation. In order to optimize clinical outcomes in patients with CRLM, awareness of current and emerging therapies and treatment strategies is essential.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. [Internet]. International Agency for Research on Cancer. 2013. Accessed on July 14, 2014. Available from: http://globocan.iarc.fr

  2. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999–2010 incidence and mortality web-based report. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013.

    Google Scholar 

  3. van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012;14(1):56–61.

    Article  PubMed  Google Scholar 

  4. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev. 2012;21(3):411–6.

    Article  PubMed  Google Scholar 

  5. Frankel TL, D’Angelica MI. Hepatic resection for colorectal metastases. J Surg Oncol. 2014;109(1):2–7.

    Article  PubMed  Google Scholar 

  6. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.

    Article  PubMed  Google Scholar 

  7. Tomlinson J, Jarnagin W, DeMatteo R, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year Survival after resection of colorectal liver metastases. J Clin Oncol. 2007;25:4575–82.

    Article  PubMed  Google Scholar 

  8. House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52. 52–5.

    Article  PubMed  Google Scholar 

  9. Spolverato G, Ejaz A, Azad N, Pawlik TM. Surgery for colorectal liver metastases: the evolution of determining prognosis. World J Gastrointest Oncol. 2013;5(12):207–21.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol. 1976;2(3):285–8.

    PubMed  CAS  Google Scholar 

  12. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199(5):502–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15(2):106–15.

    Article  Google Scholar 

  14. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007;14(3):1151–60.

    Article  PubMed  Google Scholar 

  15. Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Maccaroni E, Del Prete M, et al. The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language. Crit Rev Oncol Hematol. 2013;85:332–41.

    Article  PubMed  Google Scholar 

  16. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13(1):51–64.

    Article  PubMed  Google Scholar 

  17. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1261–8.

    Article  PubMed  Google Scholar 

  18. Gold JS, Are C, Kornprat P, Jarnagin WR, Gonen M, Fong Y, et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg. 2008;247(1):109–17.

    Article  PubMed  Google Scholar 

  19. Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15(2):91–103.

    Article  PubMed Central  Google Scholar 

  20. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.

    PubMed  Google Scholar 

  21. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15(6):933–9.

    Article  PubMed  CAS  Google Scholar 

  22. Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, et al. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11(3):318–24.

    Article  PubMed  Google Scholar 

  23. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–5.

    Article  PubMed  Google Scholar 

  24. Reddy SK, Barbas AS, Clary BM. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? Ann Surg Oncol. 2009;16(9):2395–410.

    Article  PubMed  Google Scholar 

  25. Sheth KR, Clary BM. Management of hepatic metastases from colorectal cancer. Clin Colon Rectal Surg. 2005;18(3):215–23.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

    Article  PubMed  CAS  Google Scholar 

  27. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224(3):748–56.

    Article  PubMed  Google Scholar 

  28. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology. 2010;257(1):24–39.

    Article  PubMed  Google Scholar 

  29. Leen E, Ceccotti P, Moug SJ, Glen P, MacQuarrie J, Angerson WJ, et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg. 2006;243(2):236–40.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sahani DV, Bajwa MA, Andrabi Y, Bajpai S, Cusack JC. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg. 2014;259(5):861–72.

    Article  PubMed  Google Scholar 

  31. Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol. 2007;14(2):818–26.

    Article  PubMed  CAS  Google Scholar 

  32. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939–45.

    Article  PubMed  Google Scholar 

  33. van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805–13.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ward J, Robinson PJ, Guthrie JA, Downing S, Wilson D, Lodge JP, et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology. 2005;237(1):170–80.

    Article  PubMed  Google Scholar 

  35. Holalkere NS, Sahani DV, Blake MA, Halpern EF, Hahn PF, Mueller PR. Characterization of small liver lesions: added role of MR after MDCT. J Comput Assist Tomogr. 2006;30(4):591–6.

    Article  PubMed  Google Scholar 

  36. Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57(2):421–9.

    Article  PubMed  Google Scholar 

  37. Eiber M, Fingerle AA, Brugel M, Gaa J, Rummeny EJ, Holzapfel K. Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. Eur J Radiol. 2012;81(4):683–91.

    Article  PubMed  Google Scholar 

  38. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. Radiology. 2005;237(1):123–31.

    Article  PubMed  Google Scholar 

  39. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104(12):2658–70.

    Article  PubMed  Google Scholar 

  40. Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31(1):19–31.

    Article  PubMed  Google Scholar 

  41. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–84.

    Article  PubMed  Google Scholar 

  42. Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50(7):1036–41.

    Article  PubMed  Google Scholar 

  43. Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014;311(18):1863–9.

    Article  PubMed  CAS  Google Scholar 

  44. Chun YS, Ribero D, Abdalla EK, Madoff DC, Mortenson MM, Wei SH, et al. Comparison of two methods of future liver remnant volume measurement. J Gastrointest Surg. 2008;12(1):123–8.

    Article  PubMed  Google Scholar 

  45. Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg. 2006;243(3):373–9.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005;12(1):16–22.

    Article  PubMed  Google Scholar 

  47. Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey JN. Total and segmental liver volume variations: implications for liver surgery. Surgery. 2004;135(4):404–10.

    Article  PubMed  Google Scholar 

  48. Rous P, Larimore LD. Relation of the portal blood to liver maintenance: a demonstration of liver atrophy conditional on compensation. J Exp Med. 1920;31(5):609–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10(5):803–8.

    Article  PubMed  CAS  Google Scholar 

  50. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107(5):521–7.

    PubMed  CAS  Google Scholar 

  51. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237(2):208–17.

    PubMed  PubMed Central  Google Scholar 

  52. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247(1):49–57.

    Article  PubMed  Google Scholar 

  53. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94(11):1386–94.

    Article  PubMed  CAS  Google Scholar 

  54. Shindoh J, Truty MJ, Aloia TA, Curley SA, Zimmitti G, Huang SY, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg. 2013;216(2):201–9.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Capussotti L, Muratore A, Baracchi F, Lelong B, Ferrero A, Regge D, et al. Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg. 2008;143(10):978–82. discussion 82.

    Article  PubMed  Google Scholar 

  56. de Santibanes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the “ALPPS” approach. Ann Surg. 2012;255(3):415–7.

    Article  PubMed  Google Scholar 

  57. de Santibanes E, Alvarez FA, Ardiles V. How to avoid postoperative liver failure: a novel method. World J Surg. 2012;36(1):125–8.

    Article  PubMed  Google Scholar 

  58. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3):405–14.

    Article  PubMed  Google Scholar 

  59. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254–62.

    Article  PubMed  CAS  Google Scholar 

  60. Fong Y, Fortner J, Sun R, Brennan M, Blumgart L. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg. 1999;230:309–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189(3):291–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000;231(1):59–66.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati P. Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg. 2001;25(5):638–44.

    Article  PubMed  CAS  Google Scholar 

  64. Nagashima I, Takada T, Matsuda K, Adachi M, Nagawa H, Muto T, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11(2):79–83.

    Article  PubMed  Google Scholar 

  65. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg. 2005;140(2):183–9.

    Article  PubMed  Google Scholar 

  66. Malik H, Hamandy Z, Adair R, Finch R, Al-Mukhtar A, Toogood G, et al. Prognostic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33:468–73.

    Article  PubMed  CAS  Google Scholar 

  67. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007;246(2):183–91.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ, et al. Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg. 2008;393(1):13–9.

    Article  PubMed  Google Scholar 

  69. Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125–35.

    Article  PubMed  Google Scholar 

  70. Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009;29(1):89–102.

    Article  PubMed  Google Scholar 

  71. Merkel S, Bialecki D, Meyer T, Muller V, Papadopoulos T, Hohenberger W. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol. 2009;100(5):349–57.

    Article  PubMed  Google Scholar 

  72. Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford). 2010;12(4):227–38.

    Article  Google Scholar 

  73. Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26(11):1348–53.

    Article  PubMed  Google Scholar 

  74. Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg. 2004;139(11):1168–72.

    Article  PubMed  Google Scholar 

  75. Arru M, Aldrighetti L, Castoldi R, Di Palo S, Orsenigo E, Stella M, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg. 2008;32(1):93–103.

    Article  PubMed  Google Scholar 

  76. Ayez N, Lalmahomed ZS, van der Pool AE, Vergouwe Y, van Montfort K, de Jonge J, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol. 2011;18(10):2757–63.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010;210(5):755–64. 64–6.

    Article  PubMed  Google Scholar 

  78. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17(2):572–8.

    Article  PubMed  Google Scholar 

  79. Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz Jr LA, Donehower RC, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119(23):4137–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012;106(2):123–9.

    Article  PubMed  CAS  Google Scholar 

  81. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am. 1999;5(1):34–40.

    PubMed  CAS  Google Scholar 

  82. Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol. 2003;21(3):406–12.

    Article  PubMed  CAS  Google Scholar 

  83. Domont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM, et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol. 2005;23(13):3086–93.

    Article  PubMed  CAS  Google Scholar 

  84. Smith DL, Soria JC, Morat L, Yang Q, Sabatier L, Liu DD, et al. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol. 2004;11(1):45–51.

    Article  PubMed  Google Scholar 

  85. Shimomura M, Hinoi T, Kuroda S, Adachi T, Kawaguchi Y, Sasada T, et al. Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. Ann Surg Oncol. 2013;20 Suppl 3:S527–36.

    Article  PubMed  Google Scholar 

  86. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052–61. discussion 61–4.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7(1):109–15. discussion 16–7.

    Article  PubMed  Google Scholar 

  88. Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008;8:120.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol. 2009;16(7):1844–51.

    Article  PubMed  Google Scholar 

  90. Adam R, Wicherts DA, de Haas RJ, Aloia T, Levi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26(10):1635–41.

    Article  PubMed  Google Scholar 

  91. Blazer 3rd DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.

    Article  PubMed  Google Scholar 

  92. Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg. 2009;250(6):935–42.

    Article  PubMed  Google Scholar 

  93. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304.

    Article  PubMed  CAS  Google Scholar 

  94. Ito H, Mo Q, Qin L-X, Viale A, Maithel SK, Maker AV, et al. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. PLoS One. 2013;8(12):e81680.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73(9):727–31.

    Article  PubMed  CAS  Google Scholar 

  96. Cady B, Jenkins RL, Steele Jr GD, Lewis WD, Stone MD, McDermott WV, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg. 1998;227(4):566–71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg. 2000;4(2):178–84.

    Article  PubMed  CAS  Google Scholar 

  98. Welsh FK, Tekkis PP, O’Rourke T, John TG, Rees M. Quantification of risk of a positive (R1) resection margin following hepatic resection for metastatic colorectal cancer: an aid to clinical decision-making. Surg Oncol. 2008;17(1):3–13.

    Article  PubMed  Google Scholar 

  99. Elias D, Cavalcanti A, Sabourin JC, Lassau N, Pignon JP, Ducreux M, et al. Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol. 1998;24(3):174–9.

    Article  PubMed  CAS  Google Scholar 

  100. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22. discussion 22–4.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Are C, Gonen M, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007;246(2):295–300.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Pawlik TM, Vauthey JN. Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome. Ann Surg Oncol. 2008;15(3):677–9.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Guzzetti E, Pulitano C, Catena M, Arru M, Ratti F, Finazzi R, et al. Impact of type of liver resection on the outcome of colorectal liver metastases: a case-matched analysis. J Surg Oncol. 2008;97(6):503–7.

    Article  PubMed  Google Scholar 

  104. Lalmahomed ZS, Ayez N, van der Pool AE, Verheij J, IJzermans JN, Verhoef C. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg. 2011;35(3):656–61.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Melendez JA, Arslan V, Fischer ME, Wuest D, Jarnagin WR, Fong Y, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg. 1998;187(6):620–5.

    Article  PubMed  CAS  Google Scholar 

  106. Solomon MJ, Stephen MS, Gallinger S, White GH. Does intraoperative hepatic ultrasonography change surgical decision making during liver resection? Am J Surg. 1994;168(4):307–10.

    Article  PubMed  CAS  Google Scholar 

  107. Cervone A, Sardi A, Conaway GL. Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions. Am Surg. 2000;66(7):611–5.

    PubMed  CAS  Google Scholar 

  108. Lordan JT, Stenson KM, Karanjia ND. The value of intraoperative ultrasound and preoperative imaging, individually and in combination, in liver resection for metastatic colorectal cancer. Ann R Coll Surg Engl. 2011;93(3):246–9.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Fahy B, D’Angelica M, DeMatteo R, Blumgart L, Weiser M, Ostrovnaya I, et al. Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. Ann Surg Oncol. 2009;16(2):361–70.

    Article  PubMed  Google Scholar 

  110. Aloia TA, Fahy BN. A decision analysis model predicts the optimal treatment pathway for patients with colorectal cancer and resectable synchronous liver metastases. Clin Colorectal Cancer. 2008;7(3):197–201.

    Article  PubMed  Google Scholar 

  111. Lykoudis PM, O’Reilly D, Nastos K, Fusai G. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg. 2014;101(6):605–12.

    Article  PubMed  CAS  Google Scholar 

  112. Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P, et al. Perioperative chemo with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer; a RCT. Lancet. 2008;371:1007–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. de Haas RJ, Adam R, Wicherts DA, Azoulay D, Bismuth H, Vibert E, et al. Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases. Br J Surg. 2010;97(8):1279–89.

    Article  PubMed  Google Scholar 

  114. Brouquet A, Mortenson MM, Vauthey J-N, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined, or reverse strategy? J Am Coll Surg. 2010;210:934–41.

    Article  PubMed  Google Scholar 

  115. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379–84.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Rodel C. Radiotherapy: preoperative chemoradiotherapy for rectal cancer. Nat Rev Clin Oncol. 2010;7(3):129–30.

    Article  PubMed  CAS  Google Scholar 

  117. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93(7):872–8.

    Article  PubMed  CAS  Google Scholar 

  118. Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg. 2013;148(4):385–91.

    Article  PubMed  CAS  Google Scholar 

  119. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14(12):3481–91.

    Article  PubMed  Google Scholar 

  120. Mentha G, Majno P, Terraz S, Rubbia-Brandt L, Gervaz P, Andres A, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol. 2007;33 Suppl 2:S76–83.

    Article  PubMed  Google Scholar 

  121. Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg. 2006;10(2):240–8.

    Article  PubMed  Google Scholar 

  122. Jamal MH, Hassanain M, Chaudhury P, Tran TT, Wong S, Yousef Y, et al. Staged hepatectomy for bilobar colorectal hepatic metastases. HPB (Oxford). 2012;14(11):782–9.

    Article  Google Scholar 

  123. Tsai S, Marques HP, de Jong MC, Mira P, Ribeiro V, Choti MA, et al. Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford). 2010;12(4):262–9.

    Article  Google Scholar 

  124. Cardona K, Donataccio D, Kingham TP, Allen PJ, DeMatteo RP, Fong Y, et al. Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. Ann Surg Oncol. 2014;21(3):815–21.

    Article  PubMed  Google Scholar 

  125. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007;11(11):1498–504. discussion 504–5.

    Article  PubMed  Google Scholar 

  126. Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan LA, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008;248(6):994–1005.

    Article  PubMed  Google Scholar 

  127. Kingham TP, Tanoue M, Eaton A, Rocha FG, Do R, Allen P, et al. Patterns of recurrence after ablation of colorectal cancer liver metastases. Ann Surg Oncol. 2012;19(3):834–41.

    Article  PubMed  Google Scholar 

  128. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28(13):2300–9.

    Article  PubMed  CAS  Google Scholar 

  129. Parks R, Gonen M, Kemeny N, Jarnagin W, D’Angelica M, DeMatteo R, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204(5):753–61. discussion 61–3.

    Article  PubMed  Google Scholar 

  130. Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Rague J, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50(4):478–88.

    Article  PubMed  Google Scholar 

  131. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus I-Leucovorin (i-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC); Results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol. 2002;21(S1):149a.

    Google Scholar 

  132. Lopez-Ladron A, Salvador AJ, Bernabe R. Observation versus postoperative chemotherapy after resection of liver metastases in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2003;22(373):abstr 1497.

    Google Scholar 

  133. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24(31):4976–82.

    Article  PubMed  CAS  Google Scholar 

  134. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20(12):1964–70.

    Article  PubMed  CAS  Google Scholar 

  135. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26(30):4906–11.

    Article  PubMed  CAS  Google Scholar 

  136. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72.

    Article  PubMed  CAS  Google Scholar 

  137. Bischof DA, Clary BM, Maithel SK, Pawlik TM. Surgical management of disappearing colorectal liver metastases. Br J Surg. 2013;100(11):1414–20.

    Article  PubMed  CAS  Google Scholar 

  138. Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol. 2010;17(2):492–501.

    Article  PubMed  Google Scholar 

  139. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.

    Article  PubMed  CAS  Google Scholar 

  140. Neumann UP, Thelen A, Rocken C, Seehofer D, Bahra M, Riess H, et al. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery. 2009;146(1):52–9.

    Article  PubMed  Google Scholar 

  141. Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer. 2010;116(6):1502–9.

    Article  PubMed  Google Scholar 

  142. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14(11):1691–700.

    Article  PubMed  Google Scholar 

  143. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225–39.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  144. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27(11):1829–35.

    Article  PubMed  Google Scholar 

  145. Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010;22(4):364–73.

    Article  PubMed  Google Scholar 

  146. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.

    Article  PubMed  CAS  Google Scholar 

  147. Adam R, Aloia T, Levi F, Wicherts DA, de Haas RJ, Paule B, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25(29):4593–602.

    Article  PubMed  CAS  Google Scholar 

  148. Chua TC, Saxena A, Liauw W, Chu F, Morris DL. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases--a systematic review. Eur J Cancer. 2012;48(12):1757–65.

    Article  PubMed  Google Scholar 

  149. Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol. 2005;12(11):900–9.

    Article  PubMed  Google Scholar 

  150. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, Gonen M, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol. 2009;16(8):2138–46.

    Article  PubMed  Google Scholar 

  151. Pulitano C, Bodingbauer M, Aldrighetti L, de Jong MC, Castillo F, Schulick RD, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011;18(5):1380–8.

    Article  PubMed  Google Scholar 

  152. Jones RP, Jackson R, Dunne DF, Malik HZ, Fenwick SW, Poston GJ, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99(4):477–86.

    Article  PubMed  CAS  Google Scholar 

  153. Lam VW, Pang T, Laurence JM, Johnston E, Hollands MJ, Pleass HC, et al. A systematic review of repeat hepatectomy for recurrent colorectal liver metastases. J Gastrointest Surg. 2013;17(7):1312–21.

    Article  PubMed  Google Scholar 

  154. Antoniou A, Lovegrove RE, Tilney HS, Heriot AG, John TG, Rees M, et al. Meta-analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery. 2007;141(1):9–18.

    Article  PubMed  Google Scholar 

  155. Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford). 2013;15(7):483–91.

    Article  Google Scholar 

  156. Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J. 2010;16(2):111–7.

    Article  PubMed  Google Scholar 

  157. Abdalla EK, Bauer TW, Chun YS, D’Angelica M, Kooby DA, Jarnagin WR. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford). 2013;15(2):119–30.

    Article  Google Scholar 

  158. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–71.

    Article  PubMed  PubMed Central  Google Scholar 

  159. Johnston FM, Mavros MN, Herman JM, Pawlik TM. Local therapies for hepatic metastases. J Natl Compr Canc Netw. 2013;11(2):153–60.

    PubMed  Google Scholar 

  160. Rocha FG, D’Angelica M. Treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, and microwave coagulation. J Surg Oncol. 2010;102(8):968–74.

    Article  PubMed  Google Scholar 

  161. Swaminath A, Dawson LA. Emerging role of radiotherapy in the management of liver metastases. Cancer J. 2010;16(2):150–5.

    Article  PubMed  Google Scholar 

  162. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–9.

    Article  PubMed  Google Scholar 

  163. Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–7.

    Article  PubMed  Google Scholar 

  164. Kingham TP, D’Angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol. 2010;102(8):988–95.

    Article  PubMed  Google Scholar 

  165. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10(2):176–82.

    PubMed  CAS  Google Scholar 

  166. Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat L, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57–65.

    Article  PubMed  Google Scholar 

  167. Ito K, Ito H, Kemeny NE, Gonen M, Allen PJ, Paty PB, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19(5):1609–17.

    Article  PubMed  Google Scholar 

  168. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25(35):5649–54.

    Google Scholar 

  169. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395–403.

    Article  PubMed  CAS  Google Scholar 

  170. Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888–96.

    Article  PubMed  CAS  Google Scholar 

  171. D’Angelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2014;261:353.

    Article  Google Scholar 

  172. Ammori JB, Kemeny NE, Fong Y, Cercek A, Dematteo RP, Allen PJ, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol. 2013;20(9):2901–7.

    Article  PubMed  Google Scholar 

  173. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039–48.

    Article  PubMed  CAS  Google Scholar 

  174. Ito H, Are C, Gonen M, D’Angelica M, Dematteo RP, Kemeny NE, et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247(6):994–1002.

    Article  PubMed  Google Scholar 

  175. House MG, Kemeny NE, Gonen M, Fong Y, Allen PJ, Paty PB, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254(6):851–6.

    Article  PubMed  Google Scholar 

  176. Fiorentini G, Aliberti C, Mulazzani L, Coschiera P, Catalano V, Rossi D, et al. Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res. 2014;34(2):575–84.

    PubMed  CAS  Google Scholar 

  177. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007;30(1):7–14.

    Article  PubMed  CAS  Google Scholar 

  178. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

    PubMed  CAS  Google Scholar 

  179. Saxena A, Bester L, Shan L, Perera M, Gibbs P, Meteling B, et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol. 2014;140(4):537–47.

    Article  PubMed  CAS  Google Scholar 

  180. Primrose JN. Surgery for colorectal liver metastases. Br J Cancer. 2010;102(9):1313–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  181. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection-2,804 patients. Ann Surg. 2009;250(5):831–41.

    Article  PubMed  Google Scholar 

  182. Castaing D, Vibert E, Ricca L, Azoulay D, Adam R, Gayet B. Oncologic results of laparoscopic versus open hepatectomy for colorectal liver metastases in two specialized centers. Ann Surg. 2009;250(5):849–55.

    Article  PubMed  Google Scholar 

Download references

Financial Disclosures/Conflicts of Interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael I. D’Angelica M.D., F.A.C.S. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Leal, J.N., D’Angelica, M.I. (2016). Modern Locoregional Treatment of Colorectal Cancer Liver Metastases. In: Morgan, K. (eds) Current Controversies in Cancer Care for the Surgeon. Springer, Cham. https://doi.org/10.1007/978-3-319-16205-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16205-8_5

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16204-1

  • Online ISBN: 978-3-319-16205-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics